Szpital Grochowski Im.Dr Med. Rafała Masztaka Sp. z o.o. — Clinical Trial Site

27 Registered trials

6 Currently recruiting

Organisation

Szpital Grochowski Im.Dr Med. Rafała Masztaka Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100043442

Address

Ul. Grenadierow 51/59, 04-073, Poland

Departments

5703: Oddzial Chemioterapii
8520:Oddzial Kardiologii
Cardiology
chemotherapy department
I Oddział Chorob Wewnętrznych/ Klinika Chorob Wewnetrznych Warszawskiego Uniwersytetu Medycznego
N/A
Oddzial Chemioterapii
Oddział Chemioterapii
Oddział Kardiologii
Oddział Kliniczny Kardiologii i Chorób Wewnętrznych
Oncology
Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o. Oddział Chemioterapii

Clinical trials at this site (27)

Search interface

A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Carcinoma, Transitional Cell 5
A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with… Pending

2025-523860-19-00 Non-permanent Atrial Fibrillation 10
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-520927-26-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-11-24
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC Ended

2022-502686-24-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2023-11-22
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Met… Ended

2023-505816-39-00 Untreated Locally Advanced Unresectable or Metastatic R 4 2023-04-04
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated … Ended

2023-504027-78-00 Previously Untreated Locally Advanced or Metastatic Uro 4 2023-01-13
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended

2022-502705-15-00 High-risk muscle-invasive bladder cancer 5 2021-03-08
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP… Ended

2023-504998-20-00 Metastatic Hormone-sensitive Prostate Cancer Characteri 5 2020-09-18
Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended

2023-505830-89-00 metastatic castrate resistant prostate cancer (mCRPC) 6 2020-08-05
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended

2023-510298-33-00 Prostate Cancer 4 2016-11-29
A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended

2022-502982-49-00 Metastatic Castration-Resistant Prostate Cancer 4 2024-07-15
A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended

2022-501078-20-00 Metastatic Castration-resistant Prostate Cancer 4 2023-05-15